The risk of recurring breast cancer in patients is being assessed using AI in a trial in one of the world’s leading cancer centres.
At Gustave Roussey hospital in Paris, a non-intervention clinical trial is taking place using AI to digitise more than 1,500 tissue samples from women with breast cancer.
French and US tech company Owkin has partnered with the hospital to run the trial aiming to classify patients between having a high, intermediate or low risk of their disease returning within five years.
Patients are not told of the AI results to avoid the risk of life or death treatment decisions being based on them.
This film is from Click – the BBC’s weekly technology show.
Please subscribe HERE http://bit.ly/1rbfUog
#Click #BBCNews